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enhances angiogenic factor secretion from
human mesenchymal stromal cells
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Abstract
Introduction: The in vivo therapeutic effect of mesenchymal stromal cells (MSCs) is currently believed to be
tightly linked to their paracrine secretion ability. However, insufficient or imprecise cell delivery, low cell survival
and retention post-transplant, along with harsh donor site microenvironments, are major barriers to the clinical
success of MSC therapies. Here we tested a small intestinal submucosa (SIS)-derived extracellular matrix (ECM)
bioscaffold augmented with MSCs, with the hypothesis that they will facilitate the precise delivery of increased
numbers of MSCs therefore improving cell viability and retention.
Methods: In this study, we evaluated the secretion of angiogenic factors from three human MSC lines cultured
on SIS ECM. We used human antibody array and enzyme-linked immunosorbent assay to measure the level of
angiogenic factors released from MSCs when cultured on SIS ECM or regular tissue culture plastic. We tested
MSCs cultured for three different time points.
Results: We found that the SIS ECM culture environment can significantly enhance the release of several
angiogenic factors when compared to MSCs cultured on standard tissue culture plastic. Specifically, vascular
endothelial growth factor and interleukin-8 secretion was significantly increased at 24, 48 and 72 hours
postseeding onto SIS ECM whereas vascular endothelial growth factor release for cells cultured on plastic
surface remained the same during these time points. We also observed significant donor to donor variation
in cytokine production.
Conclusions: This study demonstrates that MSCs transplanted onto a SIS ECM may greatly increase their
therapeutic potential through an increase in pro-angiogenic cytokine release.
Introduction
Mesenchymal stromal cells (MSCs) are one of the few
stem cell types to have reached late stage clinical trials
for a variety of indications, including multiple trials as
therapeutic agents for ischemic tissue repair [1–5]. In
addition to their multipotent differentiation potential, a
strong paracrine effect has been proposed as the princi-
pal mechanism that contributes to tissue repair [6–9].
The MSC treatment for ischemic heart disease (IHD) has
proven especially promising, as the pro-angiogenic, pro-
survival, and pro-immunomodulatory paracrine signals re-
leased by MSCs can rescue the native cells of an injured
heart [10–12].
The stimulation of angiogenesis is of particular im-
portance when treating cardiovascular disease, as it has
been shown that improvement in angiogenic support
accounts for amelioration of coronary artery disease
following bone marrow (BM) cell transplantation [13,
14]. BM-derived MSCs secrete angiogenic factors such
as vascular endothelial growth factor (VEGF), hepato-
cyte growth factor (HGF) and monocyte chemoattract-
ant protein 1 (MCP-1) that are critical for vascular
network remodeling [15–17]. It is this physiological
mechanism that led to the use of MSCs to treat IHD.
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Furthermore, interleukin (IL)-8, an inflammatory chemo-
kine with potent pro-angiogenic properties, is upregulated
in ischemic injuries and has been shown to promote
homing of BM-derived cells to sites of injury. A recent
study found that IL-8 induced VEGF production [18]
and that this VEGF production in human BM-derived
MSCs significantly increased the in vitro angiogenic
response compared with basal-secreted VEGF [18]. In
the present study we therefore looked at VEGF and IL-
8 secretion from MSCs as they are two key angiogenic
factors.
The majority of clinical trials using MSCs to treat
IHD have used a needle or catheter injection of thera-
peutic cells freely suspended in liquid carrier solutions.
However, it has become apparent that these methods
result in poor cell retention and survival, thus reducing
therapeutic potential [19]. Naturally derived or synthetic
materials have been explored to enhance stem cell survival
and retention in vivo [20], including alginate-, hyaluronic
acid-, collagen- or extracellular matrix (ECM)-based nat-
ural materials and synthetic peptide or polymer-based
substances. In the present study, we employed porcine
small intestinal submucosa (SIS), an ECM-based natural
material, in conjunction with our BM-derived MSCs as an
implantable device for tissue repair.
Porcine SIS is commercially available and widely used
for tissue remodeling in the clinic for various indica-
tions, including vascular and cardiac repair [21–23].
The material is derived from SIS through a process
where the ECM is decellularized while still retaining
the naturally fibrous and porous nature of the matrix as
well as several matrix-associated cytokines [24]. The
SIS ECM has been found to be superior to synthetic
materials for several indications, as it does not encap-
sulate when surgically implanted and is gradually re-
modeled leaving behind organized tissue. Currently, SIS
ECM has been used in cardiac repair and pericardial
closure in the clinic, but mainly for providing structural
support [22]. To maximize its regenerative capability,
we propose to recellularize the SIS ECM with BM-
derived MSCs, thereby combining the mechanical and
biochemical properties of the SIS ECM with the thera-
peutic capabilities of the MSCs.
The goal of this study was to assess the angiogenic
secretome changes of the combined SIS ECM and MSC
product when compared to SIS ECM or MSCs alone. In
this study, we investigated secretome changes of MSCs
after culture on SIS ECM for up to 72 hours. We then fo-
cused on two key angiogenic factors, VEGF-A and IL-8,
and analyzed their release as a function of time as well as
donor origin. Finally, we confirmed the functional rele-
vance of these secreted cytokines in promoting cardiac
endothelial cell tube formation on Matrigel, a basement
membrane purified from Engelbreth-Holm-Swarm tumor.
Materials and methods
MSC culture and characterization
All stem cell experiments were performed in accordance
with the guideline by the Institutional Stem Cell Research
Oversight committee. Primary human cells are commer-
cially available (Lonza, Walkersville, MD, USA) and their
procurement is thus not subject to institution review
board oversight.
Culture media (D20) consisted of Dulbecco's modified
Eagle's medium high glucose, 1 % L-glutamine 200 mM,
1 % penicillin-streptomycin (all Hyclone Laboratories,
South Logan, UT, USA) and 20 % fetal bovine serum
(Atlanta Biologicals, Lawrenceville, GA, USA). Porcine
SIS-derived ECM was from Cook Biotech (West Lafayette,
IN, USA).
Human MSCs from three different donors were isolated
from BM samples obtained from Lonza and tested for
putative MSC markers and tri-lineage differentiation po-
tential [25]. Briefly, cells were expanded in D20 media
before plating in adipogenic, osteogenic or chondrogenic
differentiation media according to the manufacturer’s
specifications (Lonza). Cell differentiation was visualized
by staining with Alizarin Red, Oli Red O, and Alcian Blue
for osteocytes, adipocytes and chrondrocytes, respectively.
Flow cytometric analysis was performed on cell samples
stained with CD73 (Biolegend, San Diego, CA, USA),
CD90, CD34, CD19, HLA-DR (BD Biosciences, San
Jose, CA, USA), CD105 (Abcam, Cambridge, MA,
USA), CD45, and CD14 (AbD Serotec, Raleigh, NC,
USA). Relevant isotype controls were run in parallel.
Samples were run on a FC500 and analyzed using soft-
ware supplied by the manufacturer (Beckman Coulter,
Brea, CA, USA).
Condition media collection
Cells were cultured in D20 in a 96-well plate, either on a
6-mm diameter circular SIS ECM disc or directly on the
surface of tissue culture plate. The seeding density for
both conditions was 25,000 cells/well. Conditioned media
was collected every 24 hour for 3 days for both conditions.
Fresh D20 culture media was added after each time point
for the next conditioned media collection. Two control
conditioned media groups were collected in parallel: a)
“ECM only” control consisting of an unseeded 6-mm
diameter SIS ECM disk incubated with D20 culture
media for 24 hours followed by fresh media replace-
ment and collection every 24 hours; and b) “media
only” control consisting of fresh D20 culture media col-
lected after 24 hours of incubation. Individual samples
are identified by donor number, time point and culture
condition, e.g., conditioned media collected from donor
1 cells growing on matrix for 24 hours is named “Cells
+ SIS ECM D1 24 h”.
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A subset of cells was transduced with a lentiviral vector
harboring the enhanced green fluorescent protein (eGFP)
gene in the presence of 2 mg/ml protamine sulfate. Trans-
gene expression was verified on a Motic AE30-31 inverted
fluorescence microscope at the magnification indicated
using a Moticam Pro252A imaging system (both Motic
Instruments, Canada) and further quantified on a FC500
and analyzed using software supplied by the manufacturer
(Beckman Coulter, Brea, IN, USA). Transduction efficien-
cies of >90 % eGFP positivity were routinely obtained (not
shown). Cell growth over time was estimated by plating
25,000 eGFP overexpressing MSCs on either SIS ECM or
tissue culture plastic as described above and relative eGFP
fluorescence was recorded at 24, 48, and 72 hours postseed-
ing on a Spectramax i3 imaging system (Molecular Devices,
Sunnyvale, CA, USA). Fluorescent values were corrected
for background signal from media and SIS ECM samples
alone run in parallel.
MSC angiogenic factor profiling by human angiogenesis
array
Conditioned media collected from donor 1 at the 72 hour
time point of all four culture conditions was assayed for the
expression profiles of angiogenesis-related proteins. An
R&D systems (Minneapolis, MN, USA) antibody array of
55 angiogenesis-related proteins was used in this assay
(Table 1). The LI-COR (Lincoln, NE, USA) protocol for
human angiogenesis array kit from the vendor was followed
for this assay. Array data were analyzed by LI-COR image
studio lite ver4.0 software.
ELISA analysis of VEGF and IL-8 secretion under different
culture conditions from three donors
VEGF-A (denoted VEGF only in the following) and IL-8
were detected by enzyme-linked immunosorbent assay
(ELISA) in conditioned media from three different human
donors seeded on plastic or SIS ECM, or from control
samples collected at 24, 48 or 72 hours, as described
above. Human VEGF and IL-8 ELISA kits were from R&D
systems and assays were carried out following the manu-
facturer’s description. Each datum point was analyzed in
duplicate per ELISA assay, and all ELISA experiments
were repeated three times.
In vitro angiogenic assay
Human microvascular endothelial cells (cardiac) (HMVEC-
C) and microvascular endothelial cell growth medium-2
(EGM-2 MV) culture media plus bullet kit were purchased
from Lonza. For the in vitro angiogenesis assay, Matrigel
for tube formation was purchased from Corning (Corning,
NY, USA). In vitro tube formation assays were carried out
following manufacturer’s instruction. Briefly, HMVEC-Cs
were added onto Matrigel reduced growth factor basement
membrane extract in a 96-well plate. Four different types of
conditioned media were collected from donor 1 cells at
24 hours in HMVEC-C basal media (EGM-2 MV media +
5 % fetal bovine serum). These were added into each well
to observe tube formation of HMVEC-C in different
culture conditions. EGM-2 MV complete culture media
(EGM-2 MV media + bullet kit) was used as a positive
control. Each datum point was averaged from 12 samples
assayed on a Zeiss D1 Observer (Lonza, Walkersville, MD,
USA) inverted microscope, and the images were blindly
analyzed with the ImageJ Angiogenesis Analyzer (Zeiss
Microscopy, Pleasanton, CA, USA; Image J, U. S. National
Institutes of Health, Bethesda, Maryland, USA) for length
of tubes formed, number of branches formed, number of
junctions formed, and number of nodes formed.
Statistics
All data are expressed as mean ± standard deviation.
Statistical analysis was performed using student’s t-test
with Holm-Bonferroni correction. A p < 0.05 was taken to
be significant.
Results
Human MSCs can be seeded and cultured on SIS ECM at
high density
Human BM-derived MSCs were isolated from three indi-
vidual donors and screened for tri-lineage differentiation
potential (Fig. 1a–e) and the presence of putative MSC cell
surface markers (Fig. 1g).
We transduced a subset of MSCs with a lentiviral vector
carrying the eGFP gene to allow visualization of the MSCs
once seeded onto the SIS ECM. The MSCs readily attached
to the SIS ECM (Fig. 1f) and remained viable for up to
7 days in culture as evident from the continued expression
of eGFP. Throughout the present study we used a seeding
density of 25,000 cells per well or per 6-mm matrix sample.
Differential expression of angiogenesis factors from MSCs
cultured on matrix and on plastic
Conditioned media was collected from donor 1 cells cul-
tured for 72 hours on either SIS ECM matrix or standard
tissue culture plastic. Media incubated for 72 hours with or
without matrix served as controls. Cytokine arrays were
used to measure the expression profiles of 55 angiogenic-
related proteins (Table 1 and Fig. 2). We found only min-
imal background signal in the medium only control,
whereas media incubated with matrix only reacted weakly
for fibroblast growth factor (FGF)-1 and FGF-2. In media
from cells cultured on matrix, we found relatively high ex-
pression levels of the following nine analytes: HGF,
insulin-like growth factor binding protein (IGFBP)-1,
IGFBP-3, IL-8, MCP-1, Pentraxin 3, tissue inhibitor of
metalloproteinase (TIMP)-1, urokinase-type plasminogen
activator (uPA) and VEGF. Cells on matrix express higher
levels of six of these nine analytes than cells cultured on
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plastic. Cells cultured on matrix express 14-fold HGF, 3-
fold IGFBP-1, 7-fold IL-8, 1.4-fold pentraxin 3, 2-fold uPA
and 1.8-fold VEGF when compared to cells cultured on
plastic. MCP-1 and TIMP-1 are expressed in similar con-
centrations by cells regardless of culture conditions. Only
IGFBP-3 expression levels are slightly lower in samples
from cells cultured on matrix than samples from cells cul-
ture on plastic (Fig. 2).
Quantitative measurement of VEGF and IL-8 by ELISA
We further analyzed two key angiogenic factors, VEGF and
IL-8, which showed enhanced expression from cells
cultured on matrix. We first analyzed conditioned media
from donor 1 MSCs cultured for 48 hours either on matrix
or on plastic and compared this to 48-hour matrix and
media controls by ELISA. We confirmed the increased
cytokine production of both VEGF and IL-8 from MSCs
cultured on matrix. At 48 hours, the level of VEGF was
significantly higher (6210.8 ± 1448.9 pg/ml) from cells
cultured on matrix as compared to cells cultured on plastic
(2088.4 ± 63.8 pg/ml, p = 0.008; Fig. 3a), which corresponds
to an approximate threefold increase in VEGF from cells
cultured on matrix. Similarly, we found that the IL-8 level
at the same time point was 7117.7 ± 1127.4 pg/ml from
cells cultured on matrix, which was about fourfold higher
than IL-8 from cells cultured on plastic (1844.7 ±
1488.3 pg/ml, p = 0.008; Fig. 3b). These data thus closely
mirrored what we observed in the angiogenic array blot.
Donors 2 and 3 also showed the same expression pattern of
VEGF and IL-8 (Additional file 1: Figure S1). In the matrix
and media controls, the amount of either of cytokines was
below detectable levels (Fig. 3).
Table 1 List of targets and controls of the human angiogenesis
array
Coordinate Target
A1, A2 Reference Spots








A23, A24 Reference Spots
B1, B2 Coagulation factor III
B3, B4 CXCL16
B5, B6 DPPIV (CD26)
B7, B8 EGF
B9, B10 EG-VEGF
B11, B12 Endoglin (CD105)



























Table 1 List of targets and controls of the human angiogenesis
array (Continued)
D19, D20 Platelet Factor 4 (PF4)
D21, D22 PlGF
D23, D24 Prolactin
E1, E2 Serpin B5
E3, E4 Serpin E1









F1, F2 Reference Spots
F23, F24 Negative Control
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Temporal expression pattern of VEGF and IL-8 in conditioned
media
We examined how VEGF and IL-8 levels change over
time by comparing donor 1 MSCs cultured for 24, 48
and 72 hours on matrix or on tissue culture plastic. We
again included matrix and media controls at all three
time points. VEGF levels increased as time progressed
for MSCs cultured on matrix, whereas VEGF levels
stayed the same or at a lower level when MSCs were
cultured on plastic (Fig. 4a). For cell cultures on matrix,
we found a significant difference in VEGF levels be-
tween the 24-hour and 48-hour time points (p = 0.028)
and also between the 24-hour and 72-hour time points
(p = 0.011) (Fig. 4a). IL-8 levels appeared to decrease
Fig. 1 Characterization of human MSCs cultured on SIS ECM. Human MSCs were characterized by tri-lineage induction, cell surface marker expression
and eGFP transgene expression. Cells could readily be induced along the adipogenic (a), osteogenic (b) and chondrogenic lineage (c). Non-induced
cells remained undifferentiated (d, e). f A subset of MSCs were transduced with eGFP and seeded onto SIS ECM. g MSCs stained positive by
flow cytometry for the putative MSC surface markers CD73, CD90 and CD105 (red curve). Isotype control stained cells were uniformly negative
(grey curve). Scale bars: a, b and f = 200 μm; c–e = 100 μm
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Fig. 2 Human angiogenesis array data. a Human angiogenesis array coordinates. b Scanned images of four human angiogenesis array blots. (i)
Conditioned media from human MSCs cultured on matrix for 72 hours. (ii) Conditioned media from human MSCs cultured on tissue culture plate
plastic surface for 72 hours. (iii) Matrix control, cell cultured media incubated with only matrix. (iv) Media control, cell culture media only. c Comparison
of difference in secretion of select analytes from MSCs on matrix or on plastic. Values represent the mean of fluometric intensity measurements of
duplicate dots of stained membranes depicted in (b). ECM extracellular matrix, HGF hepatocyte growth factor, IGFBP insulin-like growth factor binding
protein, IL interleukin, MCP monocyte chemoattractant protein, SIS small intestinal submucosa, TIMP tissue inhibitor of metalloproteinase, uPA
urokinase-type plasminogen activator, VEGF vascular endothelial growth factor
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slightly at 48 hours and 72 hours compared to the 24-
hour time point when cultured on matrix, although the
difference between these three time points were not
significant. MSCs cultured on plastic had much lower
IL-8 levels overall which remained the same at 24 and
48 hours with a trend towards a decline at 72 hours
(Fig. 4b). For donors 2 and 3, VEGF levels also increased
as time progressed for MSCs cultured on matrix. For
donor 2, the increase among the three time points are not
statistically significant. However, for donor 3, we also
found a significant difference in VEGF levels between the
24-hour and 48-hour time points (p = 0.043) and also be-
tween the 24-hour and 72-hour time points (p = 0.009)
(Additional file 2: Figure S2A-B). IL-8 levels varied in
three time points for MSCs cultured on matrix and the
difference is not statistically significant (Additional file 2:
Figure S2C-D).
Cell growth over time
To confirm that the difference in cytokine expression
between samples generated from cells seeded on tissue
culture plastic and cells seeded on SIS ECM was not due
to differences in cell proliferation rates, we analyzed
growth rates under the two culture conditions for up to
72 hours postseeding.
We seeded eGFP overexpressing MSCs at the same
densities as employed above and analyzed green fluores-
cence as a marker of relative cell density at 24, 48, and
72 hours postseeding. As can be seen in Fig. 5, we found
that there was no significant difference in cell density
Fig. 3 ELISA measurement of VEGF and IL-8 released from donor 1
MSCs after culture for 48 hours. Human MSCs from donor 1 were
seeded on small intestinal submucosa (SIS) extracellular matrix (ECM)
or cell culture plastic, and culture supernatant was used to quantify
a VEGF and b IL-8 secretion at 48 hours postseeding. Media and SIS
ECM only samples were used as controls. Error bars represent SD of
three biologic replicates with internal duplicates. *p < 0.05
Fig. 4 ELISA measurement of VEGF and IL-8 release from donor 1
MSCs at three different time points. Human MSCs from donor 1
were seeded on small intestinal submucosa (SIS) extracellular matrix
(ECM) or cell culture plastic and culture supernatant was used to
quantify a VEGF and b IL-8 secretion at 24, 48 and 72 hours postseeding.
Media and SIS ECM only samples were used as controls. Error bars
represent SD of three biologic replicates with internal
duplicates. *p < 0.05
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between cells seeded on SIS ECM versus cells seeded on
culture plastic at either of the three time points. This con-
firms that the observed differences in cytokine levels were
not due to differential cell growth rates relative to seeding
method. Using MSCs from donor 2, we confirmed that
there was no difference in green fluorescence between the
different time points (Additional file 3: Figure S3), neither
did we observe any difference between donor 1 and donor
2 at any of the three time points (data not shown).
Donor variability of VEGF and IL-8 release
We compared VEGF and IL-8 release from three human
donors at the 72-hour time point in culture supernatant
from cells grown on matrix or on tissue culture plastic.
We found that donor 1 has the highest secretion of IL-8
and VEGF among three donors when MSCs were cul-
tured on matrix. For IL-8 we found that donor 1 released
significantly higher levels as compared to donor 2 and 3
(p = 0.018 for donor 1 versus donor 2; p = 0.022 for donor
1 versus donor 3). For VEGF, however, the difference
among the three donors was not significant (Fig. 6). When
MSCs were cultured on plastic, VEGF and IL-8 levels were
much lower overall, and donor-to-donor variations were
not statistically significant (Fig. 6).
In vitro angiogenesis tube formation
Angiogenic potential was assessed in vitro with a tube
formation assay. HMVEC-C grown on Matrigel were
incubated with four different kinds of condition media
collected as described above in HMVEC-C basal media,
in addition to a positive control of HMVEC-C complete
culture media alone. Our data indicate that condition
media collected from human MSCs cultured on SIS ECM
for 24 hours and human MSCs cultured on plastic for
24 hours can promote endothelial cell tube formation.
However, the tube network formation is more extensive
in condition media collected from MSCs cultured on
matrix, as shown by the significantly increased length
of tubes formed (p < 0.01; Fig. 7a), number of branches
formed (p < 0.05; Fig. 7b), number of junctions formed
(p < 0.01; Fig. 7c), and number of nodes formed (p < 0.01;
Fig. 7d). Moreover, media from MSCs cultured on SIS
ECM performed as well or better than the positive control
(not significant for total length, number of junctions and
length of nodes; p = 0.0176 for number of branches)
whereas conditioned media from MSCs cultured on
plastic performed worse than the positive control for all
outcome measures except number of branches (Fig. 7;
p < 0.05 for total length of tubes, total length of nodes
and total number of junctions and p = 0.95 for total
number of branches). Two controls, HMVEC-C basal
media incubated with only SIS ECM and HMVEC-C
Fig. 5 Seeding on small intestinal submucosa (SIS) extracellular matrix
(ECM) or culture plastic does not affect cell growth rates. Human
mesenchymal stromal cells (hMSCs) from donor 1 overexpressing
enhanced green fluorescent protein (GFP) were seeded onto SIS ECM
or tissue culture plastic and relative fluorescence intensity was
measured after 24, 48 and 72 hours postseeding. Media and SIS ECM
only controls were used to correct for background fluorescence. Error
bars represent SD of six replicates. ns nonsignificant
Fig. 6 ELISA measurement of VEGF and IL-8 release from MSCs from
three human donors after culture for 72 hours. Human MSCs from
donors 1, 2 and 3 were seeded on small intestinal submucosa (SIS)
extracellular matrix (ECM) or cell culture plastic and culture
supernatant was used to quantify a VEGF and b IL-8 secretion at
72 hours postseeding. Media and SIS ECM only samples were used
as controls. Error bars represent SD of three biologic replicates with
internal duplicates. *p < 0.05
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basal media did not promote structured tube formation
(data not shown). These data demonstrate that the para-
crine factors released from our human donor MSCs are
functional and that seeding MSCs onto SIS ECM signifi-
cantly increases their angiogenic potential.
Discussions
Cell-based regenerative therapy has been intensely stud-
ied since the late 1990s, both in pre-clinical and clinical
studies. While many therapies have proven to be both
safe and efficacious, improvements in key outcome mea-
sures in many clinical trials have been modest at best.
This paucity in robust regeneration has been attributed
in part to poor cell survival and retention at the site of
transplantation and a gap in understanding of the thera-
peutic mechanism of action. In the present report, we
explore an alternative approach to delivering therapeutic
MSCs by seeding onto an implantable acellular SIS ECM
scaffold. We show that human MSCs cultured in vitro
on the SIS ECM has an improved angiogenic potential
compared to cells cultured under normal plastic adherent
conditions, potentially indicating a method for improving
survival and retention of the donor cells post-transplant
and elucidating a potential method for improving angio-
genesis in vivo. Furthermore, we demonstrate that this SIS
ECM adherence-dependent difference in secretion of
angiogenic factors is both time- and donor-dependent,
further highlighting critical parameters of optimization
of therapeutic efficacy in vivo.
In this study, we isolated human BM-derived MSCs
from three donors. We characterized MSCs by the cri-
teria as recommended by the Mesenchymal and Tissue
Stem Cell Committee of the International Society for
Cellular Therapy [25] and additionally confirmed a nor-
mal karyotype for all three donors (data not shown).
Donor to donor variability for MSCs and how it im-
pacts study outcomes is rarely assessed. Here we found
significant donor to donor variability in VEGF and IL-8
release. This observation is consistent with findings by
others who have reported significant donor to donor
differences in differentiation potential and gene expres-
sion levels of MSCs [26, 27]. The fact that we also dem-
onstrate significant differences in angiogenic secretome
levels further emphasizes the importance of using, for
example, cytokine release as screening criteria to select
optimal donor cell populations for implantation.
While we found that the pattern of increased secre-
tion of VEGF and IL-8 upon culture on SIS ECM was
consistent for the three donors presently analyzed, we
cannot formally extend that conclusion to also include
Fig. 7 In vitro tube formation using HMVEC-C. HMVEC-C were incubated with conditioned media from MSCs cultured for 24 hours on small intestinal
submucosa (SIS) extracellular matrix (ECM) or plastic tissue culture plates as indicated and angiogenic response was evaluated from photomicrographs
by calculating a total tube length, b number of branches, c number of junctions, and d number of nodes. Control samples received complete
HMVEC-C culture media. Each group is represented by the mean of 12 samples and error bars represent SD. *p < 0.05
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the other cytokines evaluated in our array experiment, as
these data currently represent only a single donor. More-
over, the present array data are also not meant to be
exhaustive with respect to factors other than IL-8 and
VEGF that may be involved in improved angiogenic sig-
naling [28]. Indeed we identified several factors that would
be interesting candidates for future work; e.g., we found
HGF, which is known to work in close concert with VEGF
to induce angiogenesis, to also be highly upregulated from
MSCs seeded on SIS ECM [29, 30].
Expansion and differentiation potentials of MSCs are
known to be dependent on the extracellular environment,
i.e., modulation of matrix stiffness can direct human
MSCs along muscle or bone lineages [31]. Similarly, vari-
ous matrices have been explored for engineering of bone
or cartilage constructs for implantation [32–34], again
focusing on differentiating donor MSCs into functional
effector cells. Less is known about the effect of undifferen-
tiated cells when cultured on acellular scaffolds in the
context of harnessing the paracrine properties of MSCs
for therapeutic application. Here, we seeded human MSCs
on SIS ECM to see if the ECM matrix would alter the
paracrine secretion ability of MSCs during culture. Using
a human angiogenesis array, we demonstrated that cultur-
ing human MSCs on SIS ECM enhanced key angiogenic
factor release when compared to human MSCs cultured
on a regular cell culture plastic surface. We then used
ELISA to confirm this finding while focusing on two im-
portant angiogenic factors, VEGF and IL-8, which showed
prominent differential expression in our array study. This
detailed analysis showed that at 48 and 72 hours, VEGF
and IL-8 secretion from MSCs cultured on matrix were
significantly higher than from cells cultured on plastic.
These findings are important for two main reasons when
MSCs are used therapeutically for their paracrine effects
on angiogenesis. First, MSCs are typically cultured on
plastic and delivered in a single-cell suspension, with
pre-implant potency testing being determined from in
vitro levels of secreted angiogenic cytokines [35–37].
Based on the present results, potency as measured by
pre-implantation levels of secreted angiogenic cytokines
from cells grown on plastic would, however, grossly
under-represent the true in vivo therapeutic potential
as the MSCs significantly alter their secretome profile
based upon their growth substrate. Second, the fact that
we found a significant increase in secretion of key an-
giogenic factors in response to in vitro culture on SIS
ECM highlights an opportunity for increasing the
therapeutic potential of MSCs by transplantation of
cell-seeded matrices rather than single-cell suspensions.
We also studied if cytokine release changed when
MSCs were cultured for 24, 48 or 72 hours. Our data
demonstrates an increase in VEGF secretion over time
for cells grown on matrix but not on plastic. Of note, we
found that the temporal increase in cytokine production
was not due to different levels of cell proliferation in
that no significant difference was observed in cell density
when comparing SIS ECM and cell culture plastic at in-
dividual time points. Collectively, these data therefore
indicated that the SIS ECM itself provided an optimized
culture environment for MSCs resulting in the release of
more cytokines that are beneficial for in vivo angiogen-
esis. Indeed, culturing MSCs on the SIS ECM for up to
72 hours, as documented in the present study, may serve
as a beneficial approach to preconditioning the MSCs-
augmented ECM patch before implantation.
This study specifically emphasizes porcine SIS ECM
bioscaffold and its effect on angiogenic-related cytokine
release from human MSCs. However, our observations
are likely to extend to ECM derived from other organs
and other species that present a three-dimensional struc-
ture and biochemical makeup that is beneficial for MSCs
and other cell types. We speculate that this may then
provide an environmental niche that better approximates
the physiological conditions in vivo. These benefits may
also not be limited to angiogenic factor release; other fac-
tors, such as immunomodulatory and anti-inflammatory
cytokines as well as those responsible for anti-apoptotic
and antimicrobial properties of MSCs, might also be
enhanced.
Conclusion
This study demonstrates that human MSCs increase their
secretion of pro-angiogenic factors in response to seeding
onto SIS ECM as compared to culture on normal tissue
culture plastic. Specifically, VEGF and IL-8 levels were
found to increase over time resulting in as much as a
three- to fourfold difference in secreted protein levels at
48 hours postseeding onto SIS ECM compared to control
cells. While the pattern of differential cytokine levels was
consistent across three different donors, we found signifi-
cant donor to donor variability, thus highlighting the need
for careful screening on potential therapeutic MSC cell
populations. Collectively these results demonstrate that
transplantation of MSCs on a SIS ECM support may hold
great potential for regenerative applications where an in-
crease in therapeutic potential through an increase in pro-
angiogenic cytokine release is essential.
Additional files
Additional file 1: Figure S1. ELISA measurement of VEGF and IL-8 from
donors 2 and 3 MSCs after culture for 48 hours. Human MSCs from
donors 2 and 3 were seeded on SIS ECM or cell culture plastic and
culture supernatant was used to quantify VEGF secretion from donor 2
(a) and donor 3 (b) and IL-8 from donor 2 (c) and donor 3 (d) at
48 hours postseeding. Media and SIS ECM only samples were used as
controls. Error bars represent SD of three biologic replicates with
internal duplicates. *p < 0.05. (TIFF 4250 kb)
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Additional file 2: Figure S2. ELISA measurement of VEGF and IL-8
release from donors 2 and 3 MSCs at three different time points.
Human MSCs from donors 2 and 3 were seeded on SIS ECM or cell culture
plastics and culture supernatant was used to quantify VEGF secretion from
donor 2 (a) and donor 3 (b) and IL-8 from donor 2 (c) and donor 3 (d) at 24,
48 and 72 hours postseeding. Error bars represent SD of three biological
replicates with internal duplicates. *p < 0.05. (TIFF 4707 kb)
Additional file 3: Figure S3. Seeding on SIS ECM or culture plastic
does not affect cell growth rates. MSCs from donor 2 overexpressing
eGFP were seeded onto SIS ECM or tissue culture plastic and relative
fluorescence intensity was measure after 24, 48 and 72 hours postseeding.
Media and SIS ECM only controls were used to correct for background
fluorescence. Error bars represent SD of six replicates. ns non-significant, RFU
relative fluorescent units. (TIFF 1443 kb)
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